伊匹木单抗联合纳武利尤单抗治疗高突变ACTH分泌性垂体癌显著有效
本文报道一例35岁女性侵袭性ACTH分泌性垂体腺癌,在替莫唑胺联合卡培他滨治疗后出现肝转移,随后接受伊匹木单抗联合纳武利尤单抗治疗,肝脏优势转移灶体积缩小92%,颅内复发病灶缩小59%,血浆ACTH从45,550 pg/mL降至66 pg/mL。分子评估显示肝转移灶存在烷化剂诱导的高突变,而未经化疗的原发肿瘤无此特征。结论提示该联合免疫治疗可能对垂体癌有效,常规化疗后复发者可通过测序识别治疗诱导的体细胞高突变。
要点
- 伊匹木单抗联合纳武利尤单抗可使垂体癌肝转移灶缩小92%、颅内复发病灶缩小59%。
- 治疗同时血浆ACTH从45,550 pg/mL降至66 pg/mL。
- 替莫唑胺耐药肝转移灶存在烷化剂诱导的高突变,可能预测免疫治疗敏感性。
核心结论
- 伊匹木单抗联合纳武利尤单抗可能是垂体癌的有效治疗选择。
- 常规化疗后复发的垂体瘤可通过临床测序识别治疗诱导的体细胞高突变,后者可能与免疫治疗反应相关。
研究设计与样本
- 病例报告:一例35岁女性侵袭性ACTH分泌性垂体腺癌。
- 分子评估采用前瞻性MSK-IMPACT临床测序和回顾性全外显子组测序,比较化疗初治垂体腺瘤与替莫唑胺耐药肝转移灶的分子改变。
主要发现
- 伊匹木单抗联合纳武利尤单抗治疗后,肝脏优势转移灶体积缩小92%,颅内复发病灶缩小59%。
- 同期血浆ACTH从45,550 pg/mL降至66 pg/mL。
- 替莫唑胺耐药肝转移灶携带与烷化剂诱导高突变一致的体细胞突变负荷,而治疗初治肿瘤无此特征。
- 替莫唑胺耐药、新致癌驱动获得及后续免疫治疗敏感性可能归因于高突变。
临床怎么用
- 对常规化疗后复发的垂体癌,可考虑伊匹木单抗联合纳武利尤单抗治疗。
- 对化疗后复发的垂体瘤进行临床测序,以识别治疗诱导的体细胞高突变。
局限性
- 本文为单例病例报告,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and few effective treatment options. CASE: A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasizing to the liver. Following treatment with ipilimumab and nivolumab, the tumor volume of the dominant liver metastasis reduced by 92%, and the recurrent intracranial disease regressed by 59%. Simultaneously, her plasma ACTH level decreased from 45,550 pg/mL to 66 pg/mL. MOLECULAR EVALUATION: Both prospective clinical sequencing with Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets and retrospective whole-exome sequencing were performed to characterize the molecular alterations in the chemotherapy-naive pituitary adenoma and the temozolomide-resistant liver metastasis. The liver metastasis harbored a somatic mutational burden consistent with alkylator-induced hypermutation that was absent from the treatment-naive tumor. Resistance to temozolomide treatment, acquisition of new oncogenic drivers, and subsequent sensitivity to immunotherapy may be attributed to hypermutation. CONCLUSION: Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma. Clinical sequencing of pituitary tumors that have relapsed following treatment with conventional chemotherapy may identify the development of therapy-induced somatic hypermutation, which may be associated with treatment response to immunotherapy.
引用
- Lin AL, Jonsson P, Tabar V, et al. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab. 2018. PMID: 30085142. doi:10.1210/jc.2018-01347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。